MURA News - Candlesense

MURA Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Mural Oncology plc Is Fair to Shareholders

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Mural Oncology plc (NASDAQ: MURA) to XOMA Royalty Corporation for $2.035 per share and...

How might the investigation and any related shareholder actions affect MURA's liquidity, short‑term volatility, and long‑term strategic outlook? What are the potential upside or downside scenarios if the sale is deemed unfair and could lead to a legal challenge or renegotiation? Is the proposed $2.035 per share price a fair valuation compared to Mural Oncology's current market price and intrinsic value?

Mergers

6 days ago

Mural Oncology Announces Entry into Agreement to be Acquired by XRA 5 Corp., a wholly owned subsidiary of XOMA Royalty for between $2.035 and $2.24 in Cash per Share

WALTHAM, Mass. and DUBLIN and EMERYVILLE, Calif., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company (“Mural”), and XOMA Royalty Corpora...

How will the acquisition impact XOMA Royalty’s balance sheet, earnings per share, and overall valuation post‑deal? What are the key closing conditions and regulatory approvals required, and what is the timeline for completion? What premium is being offered over MURA's current share price and how does it compare to recent biotech acquisition premiums?

Mergers

6 days ago

Mural Oncology Announces Entry into Agreement to be Acquired by XRA 5 Corp., a wholly owned subsidiary of XOMA Royalty for between $2.035 and $2.24 in Cash per Share

WALTHAM, Mass., DUBLIN, Ireland and EMERYVILLE, Calif., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company (“Mural”), and XOMA Royalty C...

What are the key closing conditions, regulatory approvals, and shareholder vote timelines that could affect the timing and certainty of the transaction? How does this acquisition valuation compare to recent comparable deals in the immuno‑oncology sector and to Mural's intrinsic valuation metrics? What is the expected impact of the $2.035-$2.24 per share cash offer on Mural Oncology's current stock price and trading volume?

Mergers

6 days ago